Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. / Chen, Inna M.; Johansen, Astrid Z.; Dehlendorff, Christian; Jensen, Benny V.; Bojesen, Stig E.; Pfeiffer, Per; Bjerregaard, Jon K.; Nielsen, Svend Erik; Andersen, Fahimeh; Holländer, Niels H.; Yilmaz, Mette K.; Rasmussen, Louise S.; Johansen, Julia S.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 29, No. 1, 01.2020, p. 176-184.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Chen, IM, Johansen, AZ, Dehlendorff, C, Jensen, BV, Bojesen, SE, Pfeiffer, P, Bjerregaard, JK, Nielsen, SE, Andersen, F, Holländer, NH, Yilmaz, MK, Rasmussen, LS & Johansen, JS 2020, 'Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer', Cancer Epidemiology Biomarkers and Prevention, vol. 29, no. 1, pp. 176-184. https://doi.org/10.1158/1055-9965.EPI-19-0672

APA

Chen, I. M., Johansen, A. Z., Dehlendorff, C., Jensen, B. V., Bojesen, S. E., Pfeiffer, P., ... Johansen, J. S. (2020). Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 29(1), 176-184. https://doi.org/10.1158/1055-9965.EPI-19-0672

Vancouver

Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P et al. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention. 2020 Jan;29(1):176-184. https://doi.org/10.1158/1055-9965.EPI-19-0672

Author

Chen, Inna M. ; Johansen, Astrid Z. ; Dehlendorff, Christian ; Jensen, Benny V. ; Bojesen, Stig E. ; Pfeiffer, Per ; Bjerregaard, Jon K. ; Nielsen, Svend Erik ; Andersen, Fahimeh ; Holländer, Niels H. ; Yilmaz, Mette K. ; Rasmussen, Louise S. ; Johansen, Julia S. / Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2020 ; Vol. 29, No. 1. pp. 176-184.

Bibtex

@article{3544be688194423c80f071a21380b3b9,
title = "Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer",
abstract = "Background: IL6 and YKL-40 (also known as chitinase 3-like 1 protein, CHI3L1) are produced by pancreatic cancer cells and macrophages and activate inflammation. C-reactive protein (CRP) is synthesized mainly in hepatic cells and primarily stimulated by IL6. The aim of this study was to determine the prognostic value of combined detection of serum IL6, YKL-40, and CRP in patients with pancreatic cancer receiving palliative chemotherapy. Methods: In all, 592 patients with unresectable pancreatic cancer from five hospitals in Denmark were included in the BIOPAC biomarker study between 2008 and 2017. Pretreatment and longitudinal serum values of IL6 and YKL-40 were determined. Baseline CRP and CA19-9 values were available for the whole cohort. Patients were dichotomized as low versus high using cutoffs for IL6 of >4.92 pg/mL, YKL-40 of >95{\%} age-corrected percentile, and CRP of >10 mg/L. The main outcome was overall survival. Results: Combined elevations of serum IL6, YKL-40, and CRP were associated with worse survival in contrast to an isolated high concentration of a single marker. Serum IL6, YKL-40, and CRP were higher in patients with advanced stage disease and in patients with poor performance status. Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival. Conclusions: Combined high baseline serum levels of IL6, YKL-40, and CRP are associated with poor survival. Impact: Assessment of systemic inflammation via measurements of IL6, YKL-40, and CRP may be important for pancreatic cancer prognostication.",
author = "Chen, {Inna M.} and Johansen, {Astrid Z.} and Christian Dehlendorff and Jensen, {Benny V.} and Bojesen, {Stig E.} and Per Pfeiffer and Bjerregaard, {Jon K.} and Nielsen, {Svend Erik} and Fahimeh Andersen and Holl{\"a}nder, {Niels H.} and Yilmaz, {Mette K.} and Rasmussen, {Louise S.} and Johansen, {Julia S.}",
year = "2020",
month = "1",
doi = "10.1158/1055-9965.EPI-19-0672",
language = "English",
volume = "29",
pages = "176--184",
journal = "Cancer Epidemiology, Biomarkers & Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research (A A C R)",
number = "1",

}

RIS

TY - JOUR

T1 - Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer

AU - Chen, Inna M.

AU - Johansen, Astrid Z.

AU - Dehlendorff, Christian

AU - Jensen, Benny V.

AU - Bojesen, Stig E.

AU - Pfeiffer, Per

AU - Bjerregaard, Jon K.

AU - Nielsen, Svend Erik

AU - Andersen, Fahimeh

AU - Holländer, Niels H.

AU - Yilmaz, Mette K.

AU - Rasmussen, Louise S.

AU - Johansen, Julia S.

PY - 2020/1

Y1 - 2020/1

N2 - Background: IL6 and YKL-40 (also known as chitinase 3-like 1 protein, CHI3L1) are produced by pancreatic cancer cells and macrophages and activate inflammation. C-reactive protein (CRP) is synthesized mainly in hepatic cells and primarily stimulated by IL6. The aim of this study was to determine the prognostic value of combined detection of serum IL6, YKL-40, and CRP in patients with pancreatic cancer receiving palliative chemotherapy. Methods: In all, 592 patients with unresectable pancreatic cancer from five hospitals in Denmark were included in the BIOPAC biomarker study between 2008 and 2017. Pretreatment and longitudinal serum values of IL6 and YKL-40 were determined. Baseline CRP and CA19-9 values were available for the whole cohort. Patients were dichotomized as low versus high using cutoffs for IL6 of >4.92 pg/mL, YKL-40 of >95% age-corrected percentile, and CRP of >10 mg/L. The main outcome was overall survival. Results: Combined elevations of serum IL6, YKL-40, and CRP were associated with worse survival in contrast to an isolated high concentration of a single marker. Serum IL6, YKL-40, and CRP were higher in patients with advanced stage disease and in patients with poor performance status. Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival. Conclusions: Combined high baseline serum levels of IL6, YKL-40, and CRP are associated with poor survival. Impact: Assessment of systemic inflammation via measurements of IL6, YKL-40, and CRP may be important for pancreatic cancer prognostication.

AB - Background: IL6 and YKL-40 (also known as chitinase 3-like 1 protein, CHI3L1) are produced by pancreatic cancer cells and macrophages and activate inflammation. C-reactive protein (CRP) is synthesized mainly in hepatic cells and primarily stimulated by IL6. The aim of this study was to determine the prognostic value of combined detection of serum IL6, YKL-40, and CRP in patients with pancreatic cancer receiving palliative chemotherapy. Methods: In all, 592 patients with unresectable pancreatic cancer from five hospitals in Denmark were included in the BIOPAC biomarker study between 2008 and 2017. Pretreatment and longitudinal serum values of IL6 and YKL-40 were determined. Baseline CRP and CA19-9 values were available for the whole cohort. Patients were dichotomized as low versus high using cutoffs for IL6 of >4.92 pg/mL, YKL-40 of >95% age-corrected percentile, and CRP of >10 mg/L. The main outcome was overall survival. Results: Combined elevations of serum IL6, YKL-40, and CRP were associated with worse survival in contrast to an isolated high concentration of a single marker. Serum IL6, YKL-40, and CRP were higher in patients with advanced stage disease and in patients with poor performance status. Higher IL6 and YKL-40 levels at the time of tumor progression and serum IL6 measured over time were associated with shorter overall survival. Conclusions: Combined high baseline serum levels of IL6, YKL-40, and CRP are associated with poor survival. Impact: Assessment of systemic inflammation via measurements of IL6, YKL-40, and CRP may be important for pancreatic cancer prognostication.

U2 - 10.1158/1055-9965.EPI-19-0672

DO - 10.1158/1055-9965.EPI-19-0672

M3 - Journal article

C2 - 31685562

AN - SCOPUS:85077913658

VL - 29

SP - 176

EP - 184

JO - Cancer Epidemiology, Biomarkers & Prevention

JF - Cancer Epidemiology, Biomarkers & Prevention

SN - 1055-9965

IS - 1

ER -

ID: 244368493